Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 15Triple Negative Breast Neoplasms 9Neoplasms 8Prostatic Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Polycythemia Vera 1Pathologic Complete Response 1Osteosarcoma 1Neuroendocrine Tumors 1

Interventions

Specimen Handling 2talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Adenocarcinoma × talazoparib × Clear all
NCT02282345 2022-07-06

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled 14 charts
Breast

Breast Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡